Jennifer Miles-Thomas, MD
Urology · Va Beach, VANPI 1336299494
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $66,491 of the $101,217 with a category attached, or 65.7%. AbbVie accounts for 69.5% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $24,869 and has fallen 95.7% since, to $1,079 in 2025. Among urology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 248 payments — averaging $408.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$70K
- Astellas Pharma US Inc$18K
- Boston Scientific$8K
- Medtronic$2K
- Renovia Inc$2K
- Johnson & Johnson$355
- plus $1K from 16 others
Across 1 payment — averaging $1076.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Innovation$1K
What the payments were for
- Consulting fees$17,89018%
- Speaking & faculty fees$66,49166%
- Grants$1250%
- Travel & lodging$11,12611%
- Food & beverage$5,4805%
- Education$1050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 118 | $70,319 |
| Astellas Pharma US Inc | 24 | $17,897 |
| Boston Scientific | 21 | $8,222 |
| Medtronic(2 entities) | 22 | $1,583 |
| Renovia Inc | 3 | $1,531 |
| Johnson & Johnson | 18 | $355 |
| Dendreon Pharmaceuticals LLC | 3 | $196 |
| Bayer | 8 | $192 |
| Endo Pharmaceuticals Inc. | 6 | $191 |
| Axonics, Inc. | 2 | $187 |
| Ferring Pharmaceuticals Inc. | 4 | $171 |
| Coloplast | 5 | $83 |
| Ambu Inc. | 2 | $63 |
| Neotract Inc. | 2 | $51 |
| Pfizer | 3 | $49 |
| Blue Earth Diagnostics | 1 | $22 |
| Tolmar Pharmaceuticals, Inc. | 1 | $20 |
| Acell, Inc. | 1 | $20 |
| Abbott | 1 | $18 |
| Medline Industries LP | 1 | $17 |
| Olympus America Inc. | 1 | $15 |
| Myriad Genetic Laboratories, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$101,217 in reported general payments places this provider in the 95th percentile of 300 urology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 30 | $28,232 |
| Estradiol | 35 | $1,955 |
| Tamsulosin Hcl | 51 | $756 |
| Oxybutynin Chloride ErOxybutynin Chloride | 11 | $486 |
| Solifenacin Succinate | 18 | $367 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 21 | $337 |
| Cephalexin | 74 | $311 |
| Finasteride | 18 | $109 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 32 | $103 |
| Ciprofloxacin Hcl | 21 | $45 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $19 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $17,897 | $28,23230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 300 urology providers in Virginia.
Other urology in Va Beach
- Michael FabrizioVirginia Beach$1.5M
- Gregg EureVirginia Beach$1.4M
- Jessica DelongVirginia Beach$578K
- Robert GivenVirginia Beach$157K
- Michael WilliamsVirginia Beach$144K
- Nilay GandhiWoodbridge$138K
- Shawn MarhamatiWoodbridge$130K
- Patrick WhelanSuffolk$114K
- Charles DanielRoanoke$94K
- David KageyRoanoke$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.